{"Symbol": "ASND", "AssetType": "Common Stock", "Name": "Ascendis Pharma AS", "Description": "Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.", "CIK": "1612042", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "TUBORG BOULEVARD 12, HELLERUP, DENMARK, 2900", "OfficialSite": "https://ascendispharma.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-12-31", "MarketCapitalization": "13277789000", "EBITDA": "-131415000", "PERatio": "None", "PEGRatio": "None", "BookValue": "-3.149", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-4.46", "RevenuePerShareTTM": "11.88", "ProfitMargin": "-0.317", "OperatingMarginTTM": "0.0096", "ReturnOnAssetsTTM": "-0.0686", "ReturnOnEquityTTM": "-8.18", "RevenueTTM": "720132000", "GrossProfitTTM": "625217000", "DilutedEPSTTM": "-4.46", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0.423", "AnalystTargetPrice": "285.38", "AnalystRatingStrongBuy": "3", "AnalystRatingBuy": "13", "AnalystRatingHold": "0", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "45.45", "PriceToSalesRatioTTM": "18.44", "PriceToBookRatio": "14.55", "EVToRevenue": "15.89", "EVToEBITDA": "-20.75", "Beta": "0.43", "52WeekHigh": "242", "52WeekLow": "124.06", "50DayMovingAverage": "214.51", "200DayMovingAverage": "193.77", "SharesOutstanding": "61380000", "SharesFloat": "60911000", "PercentInsiders": "0.758", "PercentInstitutions": "108.667", "DividendDate": "None", "ExDividendDate": "None"}